000292541 001__ 292541
000292541 005__ 20241106144651.0
000292541 0247_ $$2doi$$a10.3390/ph17081031
000292541 0247_ $$2pmid$$apmid:39204136
000292541 0247_ $$2pmc$$apmc:PMC11359268
000292541 037__ $$aDKFZ-2024-01784
000292541 041__ $$aEnglish
000292541 082__ $$a610
000292541 1001_ $$0P:(DE-He78)77213b583178536b3bbfd75363e8da89$$aWinter, Ruth$$b0$$eFirst author$$udkfz
000292541 245__ $$aFuture Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.
000292541 260__ $$aBasel$$bMDPI$$c2024
000292541 3367_ $$2DRIVER$$aarticle
000292541 3367_ $$2DataCite$$aOutput Types/Journal article
000292541 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1725629024_29127$$xReview Article
000292541 3367_ $$2BibTeX$$aARTICLE
000292541 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292541 3367_ $$00$$2EndNote$$aJournal Article
000292541 500__ $$a#EA:E270#LA:E270#
000292541 520__ $$aCancer is one of the most complex and challenging human diseases, with rising incidences and cancer-related deaths despite improved diagnosis and personalized treatment options. Targeted alpha therapy (TαT) offers an exciting strategy emerging for cancer treatment which has proven effective even in patients with advanced metastatic disease that has become resistant to other treatments. Yet, in many cases, more sophisticated strategies are needed to stall disease progression and overcome resistance to TαT. The combination of two or more therapies which have historically been used as stand-alone treatments is an approach that has been pursued in recent years. This review aims to provide an overview on TαT and the four main pillars of therapeutic strategies in cancer management, namely external beam radiation therapy (EBRT), immunotherapy with checkpoint inhibitors (ICI), cytostatic chemotherapy (CCT), and brachytherapy (BT), and to discuss their potential use in combination with TαT. A brief description of each therapy is followed by a review of known biological aspects and state-of-the-art treatment practices. The emphasis, however, is given to the motivation for combination with TαT as well as the pre-clinical and clinical studies conducted to date.
000292541 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000292541 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292541 650_7 $$2Other$$aalpha-emitters
000292541 650_7 $$2Other$$abrachytherapy
000292541 650_7 $$2Other$$acheckpoint inhibitors
000292541 650_7 $$2Other$$acombination therapy
000292541 650_7 $$2Other$$acytostatic chemotherapy
000292541 650_7 $$2Other$$aexternal beam radiation therapy
000292541 650_7 $$2Other$$aimmunotherapy
000292541 650_7 $$2Other$$apre-clinical and clinical studies
000292541 650_7 $$2Other$$atargeted alpha therapy
000292541 650_7 $$2Other$$atargeted radionuclide therapy
000292541 7001_ $$0P:(DE-He78)5d89608549b9211240ddca14dc023a74$$aAmghar, Mariam$$b1$$eFirst author$$udkfz
000292541 7001_ $$aWacker, Anja S$$b2
000292541 7001_ $$0P:(DE-He78)34d44e4a0656d0957d8fda31b5edb619$$aBakos, Gabor$$b3$$udkfz
000292541 7001_ $$0P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0$$aTas, Harun$$b4$$udkfz
000292541 7001_ $$0P:(DE-He78)1a25bc9516a97a13551ebd083356d24f$$aRoscher, Mareike$$b5$$udkfz
000292541 7001_ $$aKelly, James M$$b6
000292541 7001_ $$0P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aBenesova-Schäfer, Martina$$b7$$eLast author$$udkfz
000292541 773__ $$0PERI:(DE-600)2193542-7$$a10.3390/ph17081031$$gVol. 17, no. 8, p. 1031 -$$n8$$p1031$$tPharmaceuticals$$v17$$x1424-8247$$y2024
000292541 8564_ $$uhttps://inrepo02.dkfz.de/record/292541/files/pharmaceuticals-17-01031-v2.pdf
000292541 8564_ $$uhttps://inrepo02.dkfz.de/record/292541/files/pharmaceuticals-17-01031-v2.pdf?subformat=pdfa$$xpdfa
000292541 909CO $$ooai:inrepo02.dkfz.de:292541$$pVDB
000292541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77213b583178536b3bbfd75363e8da89$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5d89608549b9211240ddca14dc023a74$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34d44e4a0656d0957d8fda31b5edb619$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000292541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000292541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1a25bc9516a97a13551ebd083356d24f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000292541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f034e05cefb010f991ef8b96009d95c$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000292541 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000292541 9141_ $$y2024
000292541 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICALS-BASE : 2022$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:01:23Z
000292541 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:01:23Z
000292541 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:01:23Z
000292541 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:01:23Z
000292541 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000292541 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000292541 9202_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x0
000292541 9201_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x0
000292541 9201_ $$0I:(DE-He78)W630-20160331$$kW630$$lRadiopharmazeutika und Präklinische Studien$$x1
000292541 9200_ $$0I:(DE-He78)E270-20160331$$kE270$$lTranslationale Radiotheranostik$$x0
000292541 980__ $$ajournal
000292541 980__ $$aVDB
000292541 980__ $$aI:(DE-He78)E270-20160331
000292541 980__ $$aI:(DE-He78)W630-20160331
000292541 980__ $$aUNRESTRICTED